Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems

BACKGROUND: “Biomarker-driven targeted therapy,” the practice of tailoring patients’ treatment to the expression/activity levels of disease-specific genes/proteins, remains challenging. For example, while the anti-ERBB2 monoclonal antibody, trastuzumab, was first developed using well-characterized,...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Hae Ryung, Park, Hee Seo, Ahn, Young Zoo, Nam, Seungyoon, Jung, Hae Rim, Park, Sungjin, Lee, Sang Jin, Balch, Curt, Powis, Garth, Ku, Ja-Lok, Kim, Yon Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784390/
https://www.ncbi.nlm.nih.gov/pubmed/26955870
http://dx.doi.org/10.1186/s12885-016-2232-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784390/
https://www.ncbi.nlm.nih.gov/pubmed/26955870
http://dx.doi.org/10.1186/s12885-016-2232-2

Ejemplares similares